Discovery and development of anti-angiogenic peptides: A structural link.
Cancer is a disease promoted by excess angiogenesis. Interference with this process poses an attractive approach to controlling aberrant tumor growth, a hypothesis first proposed in the early 1970s that led to world-wide focus on identifying and developing angiogenesis inhibitors, which currently number in the hundreds. This review surveys the discovery and development of anti-angiogenic protein fragments and peptides, with a slant towards understanding their structure-function relationships to aid in the design of better therapeutic agents.
Dings
Ruud P M
RP
Department of Biochemistry, Molecular Biology and Biophysics, University of Minnesota Health Sciences Center, Minneapolis, Minnesota, USA.
Nesmelova
Irina
I
Griffioen
Arjan W
AW
Mayo
Kevin H
KH
D020533:Angiogenesis Inhibitors / Q000737:chemistry / Q000378:metabolism* / Q000627:therapeutic use; D000818:Animals; D015195:Drug Design; D042783:Endothelial Cells / Q000378:metabolism; D006801:Humans; D009389:Neovascularization, Pathologic / Q000188:drug therapy / Q000378:metabolism*; D010446:Peptide Fragments / Q000737:chemistry / Q000378:metabolism* / Q000627:therapeutic use; D010455:Peptides / Q000737:chemistry / Q000378:metabolism* / Q000627:therapeutic use; D013329:Structure-Activity Relationship
D020533:Angiogenesis Inhibitors; D010446:Peptide Fragments; D010455:Peptides